Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NUIN's Cash to Debt is ranked higher than
93% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. NUIN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NUIN' s 10-Year Cash to Debt Range
Min: 0.04  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.98
NUIN's Equity to Asset is ranked higher than
99% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. NUIN: 0.98 )
Ranked among companies with meaningful Equity to Asset only.
NUIN' s 10-Year Equity to Asset Range
Min: -2.85  Med: 0.95 Max: 0.98
Current: 0.98
-2.85
0.98
Interest Coverage No Debt
NUIN's Interest Coverage is ranked higher than
82% of the 370 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 933.44 vs. NUIN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NUIN' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 6
Z-Score: 5.20
M-Score: -3.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 70.15
NUIN's Operating margin (%) is ranked higher than
99% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.76 vs. NUIN: 70.15 )
Ranked among companies with meaningful Operating margin (%) only.
NUIN' s 10-Year Operating margin (%) Range
Min: -952.94  Med: 63.28 Max: 69.63
Current: 70.15
-952.94
69.63
Net-margin (%) 52.91
NUIN's Net-margin (%) is ranked higher than
97% of the 652 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.85 vs. NUIN: 52.91 )
Ranked among companies with meaningful Net-margin (%) only.
NUIN' s 10-Year Net-margin (%) Range
Min: -1111.76  Med: 50.50 Max: 55.46
Current: 52.91
-1111.76
55.46
ROE (%) 17.54
NUIN's ROE (%) is ranked higher than
79% of the 677 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.87 vs. NUIN: 17.54 )
Ranked among companies with meaningful ROE (%) only.
NUIN' s 10-Year ROE (%) Range
Min: 17.82  Med: 24.43 Max: 65.18
Current: 17.54
17.82
65.18
ROA (%) 16.99
NUIN's ROA (%) is ranked higher than
90% of the 697 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.99 vs. NUIN: 16.99 )
Ranked among companies with meaningful ROA (%) only.
NUIN' s 10-Year ROA (%) Range
Min: -3333.33  Med: 20.07 Max: 284.51
Current: 16.99
-3333.33
284.51
ROC (Joel Greenblatt) (%) 208.80
NUIN's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 694 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.80 vs. NUIN: 208.80 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NUIN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2025  Med: 145.60 Max: 201.75
Current: 208.8
-2025
201.75
Revenue Growth (3Y)(%) 5.40
NUIN's Revenue Growth (3Y)(%) is ranked lower than
51% of the 534 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NUIN: 5.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NUIN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 24.5
Current: 5.4
0
24.5
EBITDA Growth (3Y)(%) 9.10
NUIN's EBITDA Growth (3Y)(%) is ranked higher than
55% of the 476 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. NUIN: 9.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NUIN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -42.1  Med: -8.55 Max: 26
Current: 9.1
-42.1
26
EPS Growth (3Y)(%) 6.90
NUIN's EPS Growth (3Y)(%) is ranked higher than
52% of the 447 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. NUIN: 6.90 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NUIN' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -6.80 Max: 21.5
Current: 6.9
0
21.5
» NUIN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NUIN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 0.58
NUIN's P/E(ttm) is ranked higher than
100% of the 469 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.80 vs. NUIN: 0.58 )
Ranked among companies with meaningful P/E(ttm) only.
NUIN' s 10-Year P/E(ttm) Range
Min: 0.55  Med: 1.48 Max: 21.55
Current: 0.58
0.55
21.55
PE(NRI) 0.60
NUIN's PE(NRI) is ranked higher than
100% of the 465 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.50 vs. NUIN: 0.60 )
Ranked among companies with meaningful PE(NRI) only.
NUIN' s 10-Year PE(NRI) Range
Min: 0.56  Med: 1.48 Max: 21.55
Current: 0.6
0.56
21.55
P/B 0.08
NUIN's P/B is ranked higher than
100% of the 679 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. NUIN: 0.08 )
Ranked among companies with meaningful P/B only.
NUIN' s 10-Year P/B Range
Min: 0.08  Med: 0.27 Max: 4.81
Current: 0.08
0.08
4.81
P/S 0.28
NUIN's P/S is ranked higher than
95% of the 661 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.54 vs. NUIN: 0.28 )
Ranked among companies with meaningful P/S only.
NUIN' s 10-Year P/S Range
Min: 0.27  Med: 0.75 Max: 10.08
Current: 0.28
0.27
10.08
POCF 0.26
NUIN's POCF is ranked higher than
99% of the 399 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.21 vs. NUIN: 0.26 )
Ranked among companies with meaningful POCF only.
NUIN' s 10-Year POCF Range
Min: 0.05  Med: 1.26 Max: 5.56
Current: 0.26
0.05
5.56
PEG 0.03
NUIN's PEG is ranked higher than
100% of the 245 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. NUIN: 0.03 )
Ranked among companies with meaningful PEG only.
NUIN' s 10-Year PEG Range
Min: 0.04  Med: 0.06 Max: 0.08
Current: 0.03
0.04
0.08
Shiller P/E 0.67
NUIN's Shiller P/E is ranked higher than
99% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.23 vs. NUIN: 0.67 )
Ranked among companies with meaningful Shiller P/E only.
NUIN' s 10-Year Shiller P/E Range
Min: 0.64  Med: 2.20 Max: 46.43
Current: 0.67
0.64
46.43
Current Ratio 37.86
NUIN's Current Ratio is ranked higher than
98% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. NUIN: 37.86 )
Ranked among companies with meaningful Current Ratio only.
NUIN' s 10-Year Current Ratio Range
Min: 0.02  Med: 3.28 Max: 37.86
Current: 37.86
0.02
37.86
Quick Ratio 37.46
NUIN's Quick Ratio is ranked higher than
98% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.69 vs. NUIN: 37.46 )
Ranked among companies with meaningful Quick Ratio only.
NUIN' s 10-Year Quick Ratio Range
Min: 0.02  Med: 3.22 Max: 37.46
Current: 37.46
0.02
37.46
Days Inventory 46.28
NUIN's Days Inventory is ranked higher than
84% of the 616 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 113.37 vs. NUIN: 46.28 )
Ranked among companies with meaningful Days Inventory only.
NUIN' s 10-Year Days Inventory Range
Min: 24.63  Med: 35.15 Max: 58.39
Current: 46.28
24.63
58.39
Days Sales Outstanding 0.41
NUIN's Days Sales Outstanding is ranked higher than
99% of the 589 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.51 vs. NUIN: 0.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
NUIN' s 10-Year Days Sales Outstanding Range
Min: 0.48  Med: 0.89 Max: 214.71
Current: 0.41
0.48
214.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.09
NUIN's Price/Net Cash is ranked higher than
99% of the 184 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.71 vs. NUIN: 0.09 )
Ranked among companies with meaningful Price/Net Cash only.
NUIN' s 10-Year Price/Net Cash Range
Min: 0.12  Med: 0.38 Max: 29.76
Current: 0.09
0.12
29.76
Price/Net Current Asset Value 0.09
NUIN's Price/Net Current Asset Value is ranked higher than
100% of the 381 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.36 vs. NUIN: 0.09 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NUIN' s 10-Year Price/Net Current Asset Value Range
Min: 0.12  Med: 0.38 Max: 22.32
Current: 0.09
0.12
22.32
Price/Tangible Book 0.08
NUIN's Price/Tangible Book is ranked higher than
100% of the 615 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.30 vs. NUIN: 0.08 )
Ranked among companies with meaningful Price/Tangible Book only.
NUIN' s 10-Year Price/Tangible Book Range
Min: 0.11  Med: 0.31 Max: 5.79
Current: 0.08
0.11
5.79
Price/Projected FCF 0.07
NUIN's Price/Projected FCF is ranked higher than
99% of the 315 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. NUIN: 0.07 )
Ranked among companies with meaningful Price/Projected FCF only.
NUIN' s 10-Year Price/Projected FCF Range
Min: 0.08  Med: 0.23 Max: 3.36
Current: 0.07
0.08
3.36
Price/Median PS Value 0.38
NUIN's Price/Median PS Value is ranked higher than
95% of the 608 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. NUIN: 0.38 )
Ranked among companies with meaningful Price/Median PS Value only.
NUIN' s 10-Year Price/Median PS Value Range
Min: 0.49  Med: 1.16 Max: 13.3
Current: 0.38
0.49
13.3
Price/Peter Lynch Fair Value 0.03
NUIN's Price/Peter Lynch Fair Value is ranked higher than
99% of the 149 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.25 vs. NUIN: 0.03 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
NUIN' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.05  Med: 0.07 Max: 0.16
Current: 0.03
0.05
0.16
Price/Graham Number 0.04
NUIN's Price/Graham Number is ranked higher than
99% of the 367 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.75 vs. NUIN: 0.04 )
Ranked among companies with meaningful Price/Graham Number only.
NUIN' s 10-Year Price/Graham Number Range
Min: 0.06  Med: 0.15 Max: 2.41
Current: 0.04
0.06
2.41
Earnings Yield (Greenblatt) (%) -26.68
NUIN's Earnings Yield (Greenblatt) (%) is ranked lower than
95% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. NUIN: -26.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NUIN' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -26.68  Med: 91.80 Max: 6687.5
Current: -26.68
-26.68
6687.5
Forward Rate of Return (Yacktman) (%) 59.70
NUIN's Forward Rate of Return (Yacktman) (%) is ranked higher than
97% of the 307 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. NUIN: 59.70 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NUIN' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 14.2  Med: 410.85 Max: 1656.1
Current: 59.7
14.2
1656.1

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Nutrastar International Inc formerly known as Shuaiyi International New Resources Development Inc., was incorporated in the State of Nevada on December 22, 2002. The Company is a China-based producer and supplier of traditional Chinese medicine consumer products including commercially cultivated Cordyceps Militaris, organic and specialty food products and functional health beverages. Its flagship product is Cordyceps Militaris related consumer products, which is a species of parasitic fungus that is found in north-eastern China used for medical and health benefits. The Company also sells organic and specialty food products through its VIE Entities. Further, the Company introduced the Cordyceps based functional health beverages, a non-carbonized beverage product that contains Cordyceps Militaris and is marketed to consumers in Jiangsu and Anhui cities through its distribution channels. The Company operates in three segments: Cordyceps Militaris, organic and specialty food products and functional health beverage. The raw materials used for the products consist of carbamide, wheat, glucose, citric acid, bitter salt, peptone, and pupa powder. Its competitors in China include Liaoning Limin Cordyceps Co. Ltd., Hebei Cangzhou Cordyceps Co. Ltd., Henan Huazhong Biotech Co. Ltd., Anshan Huayu Biotech Co. Ltd., Dalian Lanshi Cordyceps Biotech Co. Ltd., Beijing Jingdu Cordyceps Biotech Co. Ltd., Ningqiang Likangfuxi Biotech Co.Ltd., Shenyang Juxin Cordyceps Co. Ltd. and Shangdong Rui Zhi Biotech Co., Ltd.
» More Articles for NUIN

Headlines

Articles On GuruFocus.com
My first article for Value ideas contest. Jan 13 2014 
Nutrastar - The Greatest Opportunity for 2014 Jan 13 2014 

More From Other Websites
NUTRASTAR INTERNATIONAL INC. Financials May 27 2015
Nutrastar International Inc. Announces First Quarter 2015 Results May 15 2015
NUTRASTAR INTERNATIONAL INC. Files SEC form 8-K, Results of Operations and Financial Condition,... May 15 2015
Nutrastar International Inc. Announces First Quarter 2015 Results May 15 2015
NUTRASTAR INTERNATIONAL INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 30 2015
Nutrastar International, Inc. Announces Full Year 2014 Results Mar 30 2015
Nutrastar International, Inc. Announces Full Year 2014 Results Mar 30 2015
Nutrastar Contracts Supplier for Production of New Cordyceps Infused Alcohol Products; Targets... Dec 18 2014
Nutrastar International, Inc. Announces Third Quarter 2014 Results Nov 13 2014
NUTRASTAR INTERNATIONAL INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 13 2014
Nutrastar International, Inc. Announces Third Quarter 2014 Results Nov 13 2014
Nutrastar Progresses Closer to International Expansion of Its Premium Cordyceps-Based Consumer... Sep 10 2014
NUTRASTAR INTERNATIONAL INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 13 2014
Nutrastar International Inc. Announces Second Quarter 2014 Results Aug 13 2014
Nutrastar Signs First Distributor for New Cordyceps Powder Solution Product, Expands Reach to... Jul 31 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK